| Field | Specification |
|---|---|
| Target | |
| Alternative names | Wiskott-Aldrich syndrome protein;WASp;WAS;IMD2; |
| UniProt # | |
| Host | |
| Clonality | |
| Isotype | |
| Reactivity | |
| Applications | |
| Immunogen | A synthetic peptide corresponding to a sequence at the C-terminus of human WASP, different from the related mouse sequence by two amino acids. |
| Molecular weight | |
| Purification | |
| Reconstitution | |
| Cellular localization | |
| Concentration | |
| Form | Lyophilized |
| Storage | |
| Catalog no. (Mfr.) | |
| Main SKU |
Product Overview
This rabbit polyclonal antibody recognizes actin nucleation-promoting factor WAS in human, mouse and rat samples and is validated for IHC, ICC/IF and Western blot. The predicted molecular weight is 52.9 kDa, and the supplier reports an observed band at about 53 kDa.
WASP is an actin nucleation-promoting factor expressed in blood cells. Activated by CDC42, it stimulates the Arp2/3 complex to build branched actin networks needed for immune synapse formation, migration and phagocytosis. Mutations cause Wiskott–Aldrich syndrome, an immunodeficiency with small platelets and eczema.
| Target | Actin nucleation-promoting factor WAS (gene WAS; UniProt P42768, human) |
|---|---|
| Host / Clonality / Isotype | Rabbit / Polyclonal / Rabbit IgG |
| Reactivity | Human, Mouse, Rat |
| Form | Lyophilized |
| Formulation | Per vial: 0.9 mg NaCl; 0.2 mg Na2HPO4; 0.05 mg NaN3; plus stabilizers |
| Calculated MW | 52.9 kDa |
| Observed MW | 53 kDa |
| Storage | As supplied: −20 °C for up to 12 months from receipt. After reconstitution: 4 °C for up to 1 month, or aliquot and keep at −20 °C for up to 6 months. Avoid repeated freeze–thaw cycles. |
Validated Applications
| Immunocytochemistry / Immunofluorescence | 0.5–1 µg/mL (Human) |
|---|---|
| IHC (frozen sections) | 0.5–1 µg/mL (Human) |
| IHC (paraffin sections) | 0.5–1 µg/mL (Human) |
| Western blot | 0.1–0.5 µg/mL (Human, Mouse, Rat) |
Samples with a confirmed band (WB): human HL-60 cells, human U937 cells, human Jurkat cells, human MCF-7 cells, rat liver tissue, mouse RAW264.7 cells.
Recommended loading (WB): 20–40 µg of total protein per lane.
Conditions in the example images (WB): 5–20% gradient SDS-PAGE under reducing conditions, 30 µg lysate per lane, transfer to nitrocellulose membrane, blocking in 5% non-fat milk, primary antibody at 0.5 µg/mL overnight at 4 °C, HRP-conjugated secondary antibody at 1:5000, ECL detection.
Samples with confirmed staining (IHC): human lung cancer tissue.
Recommended antigen retrieval: heat-mediated, in TE buffer (pH 9.0); citrate buffer (pH 6.0) can be used instead.
Conditions in the example images (IHC): heat-mediated antigen retrieval in citrate buffer (pH 6).
Samples with confirmed staining (IHC): human placenta tissue.
Samples with confirmed staining (ICC/IF): a549 cells.
Immunogen
Synthetic peptide from the C-terminal region of human WASP. It differs from the mouse sequence at two residues.
Reactivity Notes
The supplier lists reactivity with human, mouse and rat. UniProt places actin nucleation-promoting factor WAS in the cytoplasm and nucleus. Tissue expression noted by UniProt (human): Expressed predominantly in the thymus. The samples tested by the supplier (listed above) are a practical starting point for positive controls.
Safety
Customization & Add-ons: Can’t find the antibody you need—or require a custom format for your assay? We can help you source the best match or support custom antibody solutions for diverse research needs, including species and isotype selection, conjugations and labeling (e.g., HRP/AP, biotin, fluorophores), purification grade options (Protein A/G, affinity purified), formulation preferences (buffer selection, carrier-free, glycerol-free), custom concentrations and aliquoting, low-endotoxin options for cell-based work, and application-focused QC/validation support (project dependent). Click Talk to a Scientist to submit a request, email us at support@biohippo.com, or explore our Research Services for additional support—our team will follow up with feasibility details and next steps.
